Serves as the physician within oncology clinical programme teams for lung and head/neck cancers, leading medical monitoring, safety oversight and clinical data interpretation. Partners with the Senior Scientist and cross-functional teams on protocol development, regulatory interactions and investigator engagement, with on-site presence 2-3 days per week.
Serves as the physician within oncology clinical programme teams for lung and head/neck cancers, leading medical monitoring, safety oversight and clinical data interpretation across Phase I–III studies. Partners with Senior Scientists and cross-functional matrix teams on protocol development, regulatory interactions and investigator engagement, with on-site presence 2–3 days per week.
Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late pre-candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work across small molecules, biologics and antibody drug conjugates, applying AI/ML and quantitative systems pharmacology methods. Presents and defends modelling outcomes to governance boards and regulators, and contributes to protocols, analysis plans and submissions.
Leads model-informed drug development for oncology programs, defining and executing model-based strategies from late discovery through lifecycle management. Conducts population PK, exposure-response, simulation-based trial design and dose selection, applying AI/ML, quantitative systems pharmacology and model-based meta-analysis. Presents to governance boards and regulators and works across matrix teams on small molecules, biologics and antibody drug conjugates.
Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work, applying AI/ML and quantitative systems pharmacology methods, and defends results to governance boards and regulators. Sits within Oncology Translational Medicine's Clinical Pharmacology Modelling and Simulation group, working across small molecules, biologics and antibody drug conjugates.
Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work, applying AI/ML, quantitative systems pharmacology and model-based meta-analysis to small molecules, biologics and antibody drug conjugates. Presents and defends modelling outcomes to governance boards and regulators, and contributes to protocols, analysis plans and submissions.
Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work across small molecules, biologics and antibody drug conjugates, applying AI/ML and quantitative systems pharmacology methods. Presents and defends modelling outcomes to governance boards and regulators, and contributes to protocols, analysis plans and submissions.
Leads model-informed drug development for oncology programmes, defining and executing model-based strategies from late candidate selection through life cycle management. Conducts population PK, exposure-response and simulation-based trial design work, applying AI/ML and quantitative systems pharmacology methods, and defends results to governance boards and regulators. Sits within a matrixed Clinical Pharmacology Modelling and Simulation group working across small molecules, biologics and antibody drug conjugates.
Leads global development of a cancer vaccine asset from late-stage transition through approval and launch, acting as single point of accountability and chairing a cross-functional matrix Medicine Development Team spanning clinical, translational, regulatory, manufacturing and commercial. Drives strategy, go/no-go decisions and lifecycle plans for novel vaccine platforms such as mRNA and neoantigen-based therapies.
Leads global development of a cancer vaccine asset from late-stage transition through approval and launch, acting as single point of accountability across major markets. Builds and directs a matrix Medicine Development Team spanning clinical development, immunology/biomarkers, manufacturing, regulatory, safety, medical affairs and commercial, and represents the asset to senior governance boards.
Leads global development of a cancer vaccine asset from late-stage transition through approval and launch, acting as single point of accountability. Builds and leads a matrix Medicine Development Team spanning clinical development, immunology, manufacturing, regulatory, safety, medical affairs and commercial, and sets the asset strategy within GSK's oncology R&D portfolio.
Leads global development of a cancer vaccine asset from late-stage transition through approval and launch, acting as single point of accountability across major markets. Builds and directs a matrix Medicine Development Team spanning clinical development, immunology/biomarkers, manufacturing, regulatory, safety, medical affairs and commercial, and serves as asset spokesperson to senior governance boards.
Leads global development of a cancer vaccine asset from late-stage transition through approval and launch, acting as single point of accountability. Builds and leads a matrix Medicine Development Team spanning clinical development, immunology, manufacturing, regulatory, safety, medical affairs and commercial, and drives strategy, go/no-go decisions and lifecycle planning.
Leads global development of a cancer vaccine asset from late-stage transition through approval and launch, acting as single point of accountability. Builds and directs a matrix Medicine Development Team spanning clinical development, immunology, manufacturing, regulatory, safety, medical affairs and commercial, and drives strategy, go/no-go decisions and lifecycle planning.
Owns integrated Regulatory Development Plans in Planisware for GSK's HIV medicines portfolio, translating regulatory strategy into executable timelines, dependencies and deliverables. Manages FTE/resource and external project expenditure forecasting, scenario planning and portfolio insights to support governance cycles and decision-making. Partners with Global Regulatory Leads, Clinical, Safety, CMC and Finance stakeholders in a complex matrix environment.
